NKX-19 is a gene-modified cell therapy commercialized by Nkarta, with a leading Phase I program in B-Cell Chronic Lymphocytic Leukemia;Relapsed Chronic Lymphocytic Leukemia (CLL);Refractory Chronic Lymphocytic Leukemia (CLL);B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of NKX-19’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for NKX-19 is expected to reach an annual total of $297 mn by 2040 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
NKX-19 Overview
NKX-019 is under development for the treatment of B-cell malignancies including B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia (CLL/SLL), follicular lymphoma, marginal zone b-cell lymphoma, mantle cell lymphoma, waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large B-cell lymphoma, acute lymphoblastic leukemia, systemic sclerosis (scleroderma), idiopathic inflammatory myopathy (myositis) and ANCA-associated vasculitis (AAV). and lupus nephritis. The therapeutic candidate (CAR-NK) constitutes of genetically manipulated allogeneic NK cells which express a chimeric antigen receptor targeting tumor cells expressing B lymphocyte antigen CD19, transduced by gamma-retrovirus. It is administered through intravenous route.
Nkarta Overview
Nkarta is a biopharmaceutical company that primarily focuses on the development of natural killer (NK) cell therapies for the treatment of cancer. The company’s main activities focus on leveraging proprietary technology to enhance the ability of NK cells to target and destroy tumor cells. Its products include NKX101 and NKX019, that are designed to activate specific receptors and signaling pathways in NK cells to boost their tumor-fighting capabilities. The company also carries out research and development and clinical trials. Nkarta is headquartered in South San Francisco, California, the US.
The operating loss of the company was US$131.7 million in FY2023, compared to an operating loss of US$119 million in FY2022. The net loss of the company was US$117.5 million in FY2023, compared to a net loss of US$113.8 million in FY2022.
For a complete picture of NKX-19’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
